| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
The primary targets of NSC-60339 include efflux pumps, such as the AcrAB-TolC system, and the c-Met receptor. It acts as an inhibitor of efflux pumps and a substrate of AcrAB-TolC. By inhibiting efflux pumps, NSC-60339 can increase the intracellular concentration of co-administered drugs, enhancing their efficacy. The compound also targets the c-Met receptor, inhibiting its signaling and potentially reducing tumor growth and metastasis.
|
|---|---|
| ln Vitro |
In seven tumor cell lines, NSC 60339 has been linked to phthalamide treatment sensitivity, resistance, or cross-resistance in vivo. Throughout the course of the 24-hour experiment, sensitive tumors (L1210, L1210/MTX, L1210/ara-C, and P815) quickly absorbed the medication and mostly held it as a lipid-bound drug. At 0.5 hours, the drug absorption rate of the resistant tumor L1210/NSC 60339 and the two cross-resistant cancers P388/VCR and P815/VLB was equal to that of the sensitive tumors. However, within 24 hours, the resistant tumors exhibited lipid-bound drug efflux. tumors [3].
In vitro, NSC-60339 is an efflux pump inhibitor and a substrate of AcrAB-TolC. Its activity is typically measured using assays that assess the accumulation of a fluorescent efflux pump substrate in bacteria or cancer cells in the presence of the compound. The compound's ability to inhibit c-Met signaling can be assessed using kinase assays or cell-based assays that measure c-Met phosphorylation and downstream signaling. |
| ln Vivo |
In vivo, NSC-60339 has been studied as a potential cancer chemotherapeutic agent. By inhibiting efflux pumps, the compound can enhance the efficacy of cancer chemotherapeutic agents by overcoming drug resistance mechanisms. Its inhibition of c-Met signaling may also contribute to its anti-tumor activity. While specific in vivo efficacy data for NSC-60339 are not extensively detailed in the available literature, its mechanism of action suggests that it would be effective in enhancing chemotherapy efficacy and inhibiting tumor growth.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for NSC-60339 involve efflux pump inhibition assays using bacterial or cancer cell lines expressing efflux pumps. The compound's ability to inhibit efflux is assessed by measuring the accumulation of a fluorescent substrate in the presence of the compound. c-Met kinase assays can be performed to assess the compound's activity against this receptor.
|
| Cell Assay |
In vitro cellular assays for NSC-60339 are conducted in cancer cell lines. Cells are treated with varying concentrations of NSC-60339 alone or in combination with a chemotherapeutic agent, and cell proliferation is measured using MTT, CellTiter-Glo, or colony formation assays. The compound's ability to enhance the efficacy of the chemotherapeutic agent is assessed by measuring the combination index. c-Met phosphorylation and downstream signaling are assessed by western blotting.
|
| Animal Protocol |
In vivo animal studies for NSC-60339 would typically be conducted in mouse xenograft models using cancer cell lines. Animals would be administered NSC-60339 alone or in combination with a chemotherapeutic agent, and tumor growth inhibition would be monitored. The compound's ability to enhance the efficacy of the chemotherapeutic agent would be assessed. Pharmacokinetic studies would be performed to determine the compound's bioavailability, half-life, and tissue distribution.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NSC-60339 indicate that it has a molecular weight of 486.95 and a molecular formula of C26H23ClN6O2. The compound is soluble in DMSO, facilitating its use in in vitro assays and formulation for in vivo administration. For storage, the powder should be kept at -20°C for up to 3 years or at 4°C for up to 2 years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of NSC-60339 is primarily derived from its use as a research compound in preclinical studies. As an efflux pump inhibitor and c-Met inhibitor, potential on-target effects could include changes in drug disposition and tumor growth. Comprehensive toxicology studies would be required for therapeutic development, including assessments of drug interactions and organ function.
|
| References |
[1]. D. W. Yesair, et al. Relationship of Phthalanilide-Lipid Complexes to Uptake and Retention of 2-Chloro-4′,4″-di(2-imidazolin-2-yl)terephthalanilide (NSC 60339) by Sensitive and Resistant P388 Leukemia Cells. CANCER RESEARCH 26 Part 1: 202-207, February 19
[2]. Yesair DW, et al. The retention or efflux of phthalanilide (NSC 60339)-lipid complexes by sensitive or resistant murine tumor cells and Escherichia coli B. Cancer Res. 1968 Feb;28(2):314-9. [3]. Haynes KM, et al. Identification and Structure-Activity Relationships of Novel Compounds that Potentiate the Activities of Antibiotics in Escherichia coli. J Med Chem. 2017 Jul 27;60(14):6205-6219. [4]. Abdali N, et al. Reviving Antibiotics: Efflux Pump Inhibitors That Interact with AcrA, a Membrane Fusion Protein of the AcrAB-TolC Multidrug Efflux Pump. ACS Infect Dis. 2017 Jan 13;3(1):89-98. |
| Additional Infomation |
NSC-60339 is an efflux pump inhibitor and a substrate of AcrAB-TolC. It is a polybasic terephthalic acid derivative studied as a potential cancer chemotherapeutic agent. The compound also targets the c-Met receptor. NSC-60339 is not approved for clinical use and is available from research chemical suppliers for preclinical studies.
|
| Molecular Formula |
C26H23CLN6O2
|
|---|---|
| Molecular Weight |
486.96
|
| Exact Mass |
486.157
|
| Elemental Analysis |
C, 64.13; H, 4.76; Cl, 7.28; N, 17.26; O, 6.57
|
| CAS # |
70-09-7
|
| Related CAS # |
70-09-7;
|
| PubChem CID |
65558
|
| Appearance |
Solid powder
|
| LogP |
3.219
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
832
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN=C(N1)C2=CC=C(C=C2)NC(=O)C3=CC(=C(C=C3)C(=O)NC4=CC=C(C=C4)C5=NCCN5)Cl
|
| InChi Key |
UJQGBYRKCZQJJS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H23ClN6O2/c27-22-15-18(25(34)32-19-6-1-16(2-7-19)23-28-11-12-29-23)5-10-21(22)26(35)33-20-8-3-17(4-9-20)24-30-13-14-31-24/h1-10,15H,11-14H2,(H,28,29)(H,30,31)(H,32,34)(H,33,35)
|
| Chemical Name |
2-Chloro-4',4''-di-2-imidazolin-2-yl-terephthalanilide
|
| Synonyms |
NSC-60339; NSC 60339; NSC60339; Phthalanilide; Wander;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~10.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0536 mL | 10.2678 mL | 20.5356 mL | |
| 5 mM | 0.4107 mL | 2.0536 mL | 4.1071 mL | |
| 10 mM | 0.2054 mL | 1.0268 mL | 2.0536 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
